These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38349675)

  • 1. Letter to the Editor: AGILE 3+ score, enhancing the diagnostic accuracy of advanced fibrosis in patients with nonalcoholic fatty liver disease.
    Calzadilla-Bertot L; Jeffrey AW; Jeffrey GP
    Hepatology; 2024 Jun; 79(6):E153-E154. PubMed ID: 38349675
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply: AGILE 3+ score, enhancing the diagnostic accuracy of advanced fibrosis in patients with nonalcoholic fatty liver disease.
    Lombardi R; Dalbeni A; Mantovani A; Ravaioli F
    Hepatology; 2024 Jun; 79(6):E155-E156. PubMed ID: 38349677
    [No Abstract]   [Full Text] [Related]  

  • 3. Letter to the editor: diagnosing fibrosis and cirrhosis in nonalcoholic fatty liver disease using machine learning models.
    Feng Y; Peng B; Li Y; Sun L; Sun Y
    Hepatology; 2023 May; 77(5):E103-E104. PubMed ID: 36645222
    [No Abstract]   [Full Text] [Related]  

  • 4. Diabetes Liver Fibrosis Score to Detect Advanced Fibrosis in Diabetics with Nonalcoholic Fatty Liver Disease.
    Singh A; Garg R; Lopez R; Alkhouri N
    Clin Gastroenterol Hepatol; 2022 Mar; 20(3):e624-e626. PubMed ID: 33434655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The evaluation of hepatic fibrosis scores in children with nonalcoholic fatty liver disease.
    Mansoor S; Yerian L; Kohli R; Xanthakos S; Angulo P; Ling S; Lopez R; Christine CK; Feldstein AE; Alkhouri N
    Dig Dis Sci; 2015 May; 60(5):1440-7. PubMed ID: 25540086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes.
    Pennisi G; Enea M; Falco V; Aithal GP; Palaniyappan N; Yilmaz Y; Boursier J; Cassinotto C; de Lédinghen V; Chan WK; Mahadeva S; Eddowes P; Newsome P; Karlas T; Wiegand J; Wong VW; Schattenberg JM; Labenz C; Kim W; Lee MS; Lupsor-Platon M; Cobbold JFL; Fan JG; Shen F; Staufer K; Trauner M; Stauber R; Nakajima A; Yoneda M; Bugianesi E; Younes R; Gaia S; Zheng MH; Cammà C; Anstee QM; Mózes FE; Pavlides M; Petta S
    Hepatology; 2023 Jul; 78(1):195-211. PubMed ID: 36924031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.
    Patel YA; Gifford EJ; Glass LM; Turner MJ; Han B; Moylan CA; Choi S; Suzuki A; Provenzale D; Hunt CM
    Dig Dis Sci; 2018 Sep; 63(9):2259-2266. PubMed ID: 29779083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and Validation of Hepamet Fibrosis Scoring System-A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis.
    Ampuero J; Pais R; Aller R; Gallego-Durán R; Crespo J; García-Monzón C; Boursier J; Vilar E; Petta S; Zheng MH; Escudero D; Calleja JL; Aspichueta P; Diago M; Rosales JM; Caballería J; Gómez-Camarero J; Lo Iacono O; Benlloch S; Albillos A; Turnes J; Banales JM; Ratziu V; Romero-Gómez M;
    Clin Gastroenterol Hepatol; 2020 Jan; 18(1):216-225.e5. PubMed ID: 31195161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gamma-glutamyl transferase and cardiovascular risk in nonalcoholic fatty liver disease: The Gut and Obesity Asia initiative.
    Pitisuttithum P; Chan WK; Goh GB; Fan JG; Song MJ; Charatcharoenwitthaya P; Duseja A; Dan YY; Imajo K; Nakajima A; Ho KY; Goh KL; Wong VW; Treeprasertsuk S
    World J Gastroenterol; 2020 May; 26(19):2416-2426. PubMed ID: 32476802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modified thresholds for fibrosis risk scores in nonalcoholic fatty liver disease are necessary in the obese.
    Ooi GJ; Burton PR; Doyle L; Wentworth JM; Bhathal PS; Sikaris K; Cowley MA; Roberts SK; Kemp W; O'Brien PE; Brown WA
    Obes Surg; 2017 Jan; 27(1):115-125. PubMed ID: 27220852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accuracy of Noninvasive Fibrosis Scores to Detect Advanced Fibrosis in Patients With Type-2 Diabetes With Biopsy-proven Nonalcoholic Fatty Liver Disease.
    Singh A; Gosai F; Siddiqui MT; Gupta M; Lopez R; Lawitz E; Poordad F; Carey W; McCullough A; Alkhouri N
    J Clin Gastroenterol; 2020; 54(10):891-897. PubMed ID: 32168133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Noninvasive scores are poorly predictive of histological fibrosis in paediatric fatty liver disease.
    Kalveram L; Baumann U; De Bruyne R; Draijer L; Janczyk W; Kelly D; Koot BG; Lacaille F; Lefere S; Lev HM; Lubrecht J; Mann JP; Mosca A; Rajwal S; Socha P; Vreugdenhil A; Alisi A; Hudert CA;
    J Pediatr Gastroenterol Nutr; 2024 Jan; 78(1):27-35. PubMed ID: 38291699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Agile scores are a good predictor of liver-related events in patients with NAFLD.
    Nakatsuka T; Tateishi R; Sato M; Fujishiro M; Koike K
    J Hepatol; 2023 Sep; 79(3):e126-e127. PubMed ID: 36870612
    [No Abstract]   [Full Text] [Related]  

  • 14. Ability of Cytokeratin-18 Fragments and FIB-4 Index to Diagnose Overall and Mild Fibrosis Nonalcoholic Steatohepatitis in Japanese Nonalcoholic Fatty Liver Disease Patients.
    Kobayashi N; Kumada T; Toyoda H; Tada T; Ito T; Kage M; Okanoue T; Kudo M
    Dig Dis; 2017; 35(6):521-530. PubMed ID: 29040984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epoxygenase-Derived Epoxyeicosatrienoic Acid Mediators Are Associated With Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, and Fibrosis.
    Arvind A; Osganian SA; Sjoquist JA; Corey KE; Simon TG
    Gastroenterology; 2020 Dec; 159(6):2232-2234.e4. PubMed ID: 32768596
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical Utility of Change in Nonalcoholic Fatty Liver Disease Activity Score and Change in Fibrosis in NAFLD.
    Tamaki N; Munaganuru N; Jung J; Yonan AQ; Bettencourt R; Ajmera V; Valasek MA; Behling C; Loomba R
    Clin Gastroenterol Hepatol; 2021 Dec; 19(12):2673-2674.e3. PubMed ID: 33157318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic Performance of Serum Asialo-α1-acid Glycoprotein for Advanced Liver Fibrosis or Cirrhosis in Patients with Chronic Hepatitis B or Nonalcoholic Fatty Liver Disease.
    Kim SU; Jeon MY; Lim TS
    Korean J Gastroenterol; 2019 Dec; 74(6):341-348. PubMed ID: 31870140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Presentation and Patient Evaluation in Nonalcoholic Fatty Liver Disease.
    Patel V; Sanyal AJ; Sterling R
    Clin Liver Dis; 2016 May; 20(2):277-92. PubMed ID: 27063269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accuracy of Noninvasive Fibrosis Scoring Systems in African American and White Patients With Nonalcoholic Fatty Liver Disease.
    Marella HK; Reddy YK; Jiang Y; Ganguli S; Podila PSB; Snell PD; Kovalic AJ; Cholankeril G; Singal AK; Nair S; Maliakkal B; Satapathy SK
    Clin Transl Gastroenterol; 2020 Apr; 11(4):e00165. PubMed ID: 32352687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accurate diagnosis of NAFLD-related hepatic fibrosis with non-invasive methods: A comment for moving forward.
    Li W
    J Hepatol; 2020 Aug; 73(2):465-466. PubMed ID: 32416974
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.